Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06182072 · ClinicalTrials.gov registry record · Phase 1
ProAgio in Pancreatic Ductal Adenocarcinoma (PDAC)
A Phase 1 study of Pancreatic Ductal Adenocarcinoma (PDAC), sponsored by ProDa BioTech.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 46
- Enrollment target
- 1
- Study location
NCT06182072: Recruiting Phase 1 study of Pancreatic Ductal Adenocarcinoma (PDAC), sponsored by ProDa BioTech.
NCT06182072 is a Phase 1 study of Pancreatic Ductal Adenocarcinoma (PDAC) that is actively recruiting participants, run by ProDa BioTech. The registered enrollment target is 46 participants, below the 294-participant average among 16 other Pancreatic Ductal Adenocarcinoma (PDAC) trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06182072, a Phase 1 study of Pancreatic Ductal Adenocarcinoma (PDAC), is actively recruiting participants, sponsored by ProDa BioTech.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 46 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an open-label Phase I/Ib dose-escalation, dose-expansion clinical trial of the safety, pharmacokinetics and clinical activity of ProAgio combined with gemcitabine, nab-paclitaxel (G-nP) or gemcitabine, nab-paclitaxel (G-nP) and atezolizumab in previously untreated subjects with metastatic pancreatic ductal adenocarcinoma (PDAC)
Primary Outcome
Physical examination, vital signs, clinical laboratory evaluations (CBC, serum chemistry, coagulation studies, LFTs, and assessment of subject reported AEs (via CTCAE v5.0) and SAEs will be used to evaluate safety.
Conditions Studied
Interventions
- DRUG ProAgio Dose Levels (DL) 1,2,3,4
- DRUG Gemcitabine, nab paclitaxel
Study Locations (1)
Alabama
- O'Neal Comprehensive Cancer Center, University of Alabama - Birmingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2023-09-14 |
| Est. Completion | 2028-06-30 |
| Phase | Phase 1 |
What NCT06182072 shows while recruiting
NCT06182072 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 46 participants, a relatively small participant target, below the 294-participant average among 16 other Pancreatic Ductal Adenocarcinoma (PDAC) trials with a reported enrollment target (84% lower).
The record links to 1 condition, with Pancreatic Ductal Adenocarcinoma (PDAC) appearing as the primary indexed condition, and to 2 interventions - of which ProAgio Dose Levels (DL) 1,2,3,4 is the first listed.
NCT06182072 reports a single indexed study location in Alabama.
Frequently Asked Questions
What is clinical trial NCT06182072 about?
NCT06182072 is a clinical study titled "ProAgio in Pancreatic Ductal Adenocarcinoma (PDAC)". This is an open-label Phase I/Ib dose-escalation, dose-expansion clinical trial of the safety, pharmacokinetics and clinical activity of ProAgio combined with gemcitabine, nab-paclitaxel (G-nP) or gemcitabine, nab-paclitaxel (G-nP) and atezolizumab in previously untreated subjects with metastatic pa...
What is the current status of trial NCT06182072?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 46 participants. The study started on 2023-09-14. Estimated completion is 2028-06-30.
What conditions does trial NCT06182072 study?
This clinical trial studies the following conditions: Pancreatic Ductal Adenocarcinoma (PDAC).
What interventions are being tested in trial NCT06182072?
The interventions under investigation include: ProAgio Dose Levels (DL) 1,2,3,4 (DRUG), Gemcitabine, nab paclitaxel (DRUG).
Who is sponsoring clinical trial NCT06182072?
This trial is sponsored by ProDa BioTech, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06182072 being conducted?
This trial has 1 study location across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Ductal Adenocarcinoma (PDAC)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06182072's enrollment target sits among peer trials
46 12th of 16 higher than 5 of 16 other Pancreatic Ductal Adenocarcinoma (PDAC) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pancreatic Ductal Adenocarcinoma (PDAC) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
RECRUITING · Phase 1
-
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
RECRUITING · Phase 1
-
Intraperitoneal Paclitaxel With NALIRIFOX for Pancreatic Ductal Adenocarcinoma With Peritoneal Carcinomatosis
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01890590 · 46 participants · NA
A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma
- NCT03191149 · 46 participants · Phase 2
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
- NCT03510208 · 46 participants · Phase 1
Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery
- NCT04048278 · 46 participants · Early Phase 1
Lidocaine Infusion in Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI